AU2021235257B2 - GPR52 modulator compounds - Google Patents
GPR52 modulator compoundsInfo
- Publication number
- AU2021235257B2 AU2021235257B2 AU2021235257A AU2021235257A AU2021235257B2 AU 2021235257 B2 AU2021235257 B2 AU 2021235257B2 AU 2021235257 A AU2021235257 A AU 2021235257A AU 2021235257 A AU2021235257 A AU 2021235257A AU 2021235257 B2 AU2021235257 B2 AU 2021235257B2
- Authority
- AU
- Australia
- Prior art keywords
- fluoro
- trifluoromethyl
- benzyl
- pyrazole
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Amplifiers (AREA)
- Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2003668.7 | 2020-03-13 | ||
| GBGB2003668.7A GB202003668D0 (en) | 2020-03-13 | 2020-03-13 | GPR52 Modulator compounds |
| PCT/GB2021/050638 WO2021181122A1 (en) | 2020-03-13 | 2021-03-15 | Gpr52 modulator compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2021235257A1 AU2021235257A1 (en) | 2022-10-06 |
| AU2021235257B2 true AU2021235257B2 (en) | 2026-07-16 |
Family
ID=70453676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021235257A Active AU2021235257B2 (en) | 2020-03-13 | 2021-03-15 | GPR52 modulator compounds |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US12655120B2 (enExample) |
| EP (1) | EP4117784B1 (enExample) |
| JP (1) | JP7492597B2 (enExample) |
| KR (1) | KR20220152296A (enExample) |
| CN (1) | CN115515681B (enExample) |
| AU (1) | AU2021235257B2 (enExample) |
| BR (1) | BR112022018287A2 (enExample) |
| CA (1) | CA3175429A1 (enExample) |
| DK (1) | DK4117784T3 (enExample) |
| ES (1) | ES2992600T3 (enExample) |
| FI (1) | FI4117784T3 (enExample) |
| GB (1) | GB202003668D0 (enExample) |
| HR (1) | HRP20241375T1 (enExample) |
| HU (1) | HUE068758T2 (enExample) |
| IL (1) | IL296413B2 (enExample) |
| LT (1) | LT4117784T (enExample) |
| MX (1) | MX2022011333A (enExample) |
| PL (1) | PL4117784T3 (enExample) |
| PT (1) | PT4117784T (enExample) |
| RS (1) | RS66063B1 (enExample) |
| SI (1) | SI4117784T1 (enExample) |
| SM (1) | SMT202400402T1 (enExample) |
| WO (1) | WO2021181122A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202003668D0 (en) | 2020-03-13 | 2020-04-29 | Heptares Therapeutics Ltd | GPR52 Modulator compounds |
| EP4139284A1 (en) | 2020-04-22 | 2023-03-01 | Neurocrine Biosciences, Inc. | Gpr52 modulators and methods of use |
| EP4330232A1 (en) * | 2021-04-26 | 2024-03-06 | Neurocrine Biosciences, Inc. | Gpr52 modulators and methods of use |
| GB202113186D0 (en) | 2021-09-15 | 2021-10-27 | Heptares Therapeutics Ltd | GPR52 Modulator compounds |
| WO2024091541A1 (en) * | 2022-10-26 | 2024-05-02 | Neurocrine Biosciences, Inc. | Compounds and compositions as gpr52 modulators |
| WO2024091542A1 (en) * | 2022-10-26 | 2024-05-02 | Neurocrine Biosciences, Inc. | Compounds and compositions as gpr52 modulators |
| AR130864A1 (es) * | 2022-10-26 | 2025-01-29 | Neurocrine Biosciences Inc | Compuestos y composiciones como moduladores de gpr52 |
| WO2025252061A1 (zh) * | 2024-06-04 | 2025-12-11 | 海思科医药集团股份有限公司 | 一种gpr52激动剂及其在医药上的应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019053090A1 (en) * | 2017-09-13 | 2019-03-21 | Novartis Ag | DIPHENYL DERIVATIVES AND USES THEREOF |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2327185A1 (en) | 1998-04-08 | 1999-10-14 | Abbott Laboratories | Pyrazole inhibitors of cytokine production |
| US20010044445A1 (en) | 1999-04-08 | 2001-11-22 | Bamaung Nwe Y. | Azole inhibitors of cytokine production |
| NZ526624A (en) | 2000-12-22 | 2005-07-29 | Ortho Mcneil Pharm Inc | Substituted triazole diamine derivatives as kinase inhibitors |
| US20040220170A1 (en) | 2003-05-01 | 2004-11-04 | Atkinson Robert N. | Pyrazole-amides and sulfonamides as sodium channel modulators |
| WO2005037797A1 (en) * | 2003-10-21 | 2005-04-28 | Pharmacia Corporation | Substituted pyrazole urea compounds for the treatment of inflammation |
| JPWO2009107391A1 (ja) | 2008-02-27 | 2011-06-30 | 武田薬品工業株式会社 | ６員芳香環含有化合物 |
| KR20100097077A (ko) | 2009-02-25 | 2010-09-02 | 주식회사 중외제약 | Ｈｓｐ90에 대한 억제 효능을 갖는 피리디논 유도체 |
| EP2518054A1 (en) | 2009-12-24 | 2012-10-31 | Takeda Pharmaceutical Company Limited | Amide compound |
| EP2530078A1 (en) | 2010-01-27 | 2012-12-05 | Takeda Pharmaceutical Company Limited | Thiazole derivative |
| GB201317363D0 (en) | 2013-10-01 | 2013-11-13 | Eisai Ltd | Novel compounds |
| MX373876B (es) * | 2015-04-29 | 2020-03-26 | Arena Pharm Inc | 1-heteroaril-indolin-4-carboxamidas como moduladores de gpr52 útiles para el tratamiento o prevención de trastornos relacionados a las mismas. |
| WO2017077280A1 (en) | 2015-11-02 | 2017-05-11 | Sonia Lain | Tetrahydroindazoles and medical uses thereof |
| US11279703B2 (en) | 2016-12-01 | 2022-03-22 | Aptose Biosciences Inc. | Fused pyrimidine compounds as BRD4 and JAK2 dual inhibitors and methods for use thereof |
| JP7425724B2 (ja) | 2017-10-17 | 2024-01-31 | エピザイム，インコーポレイティド | Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物及びその誘導体 |
| AU2018353150B2 (en) | 2017-10-18 | 2024-06-06 | Epizyme, Inc. | Methods of using EHMT2 inhibitors in treating or preventing blood disorders |
| US20210213014A1 (en) | 2017-10-18 | 2021-07-15 | Epizyme, Inc. | Methods of using ehmt2 inhibitors in immunotherapies |
| CN114650992A (zh) | 2019-11-08 | 2022-06-21 | 赫普泰雅治疗有限公司 | Gpr52调节剂化合物 |
| GB202003668D0 (en) | 2020-03-13 | 2020-04-29 | Heptares Therapeutics Ltd | GPR52 Modulator compounds |
| GB202013558D0 (en) | 2020-08-28 | 2020-10-14 | Heptares Therapeutics Ltd | GRP52 Modularor compounds |
-
2020
- 2020-03-13 GB GBGB2003668.7A patent/GB202003668D0/en not_active Ceased
-
2021
- 2021-03-15 ES ES21713103T patent/ES2992600T3/es active Active
- 2021-03-15 IL IL296413A patent/IL296413B2/en unknown
- 2021-03-15 KR KR1020227035100A patent/KR20220152296A/ko active Pending
- 2021-03-15 WO PCT/GB2021/050638 patent/WO2021181122A1/en not_active Ceased
- 2021-03-15 MX MX2022011333A patent/MX2022011333A/es unknown
- 2021-03-15 LT LTEPPCT/GB2021/050638T patent/LT4117784T/lt unknown
- 2021-03-15 AU AU2021235257A patent/AU2021235257B2/en active Active
- 2021-03-15 HU HUE21713103A patent/HUE068758T2/hu unknown
- 2021-03-15 SI SI202130212T patent/SI4117784T1/sl unknown
- 2021-03-15 PL PL21713103.6T patent/PL4117784T3/pl unknown
- 2021-03-15 HR HRP20241375TT patent/HRP20241375T1/hr unknown
- 2021-03-15 RS RS20241089A patent/RS66063B1/sr unknown
- 2021-03-15 DK DK21713103.6T patent/DK4117784T3/da active
- 2021-03-15 EP EP21713103.6A patent/EP4117784B1/en active Active
- 2021-03-15 JP JP2022555137A patent/JP7492597B2/ja active Active
- 2021-03-15 BR BR112022018287A patent/BR112022018287A2/pt unknown
- 2021-03-15 US US17/909,792 patent/US12655120B2/en active Active
- 2021-03-15 FI FIEP21713103.6T patent/FI4117784T3/fi active
- 2021-03-15 PT PT217131036T patent/PT4117784T/pt unknown
- 2021-03-15 CN CN202180033813.9A patent/CN115515681B/zh active Active
- 2021-03-15 SM SM20240402T patent/SMT202400402T1/it unknown
- 2021-03-15 CA CA3175429A patent/CA3175429A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019053090A1 (en) * | 2017-09-13 | 2019-03-21 | Novartis Ag | DIPHENYL DERIVATIVES AND USES THEREOF |
Also Published As
| Publication number | Publication date |
|---|---|
| IL296413B1 (en) | 2025-11-01 |
| KR20220152296A (ko) | 2022-11-15 |
| HUE068758T2 (hu) | 2025-01-28 |
| IL296413A (en) | 2022-11-01 |
| HRP20241375T1 (hr) | 2024-12-20 |
| FI4117784T3 (fi) | 2024-10-10 |
| PL4117784T3 (pl) | 2025-01-13 |
| JP2023519666A (ja) | 2023-05-12 |
| IL296413B2 (en) | 2026-03-01 |
| SMT202400402T1 (it) | 2024-11-15 |
| WO2021181122A1 (en) | 2021-09-16 |
| DK4117784T3 (da) | 2024-10-14 |
| BR112022018287A2 (pt) | 2022-11-22 |
| MX2022011333A (es) | 2022-12-08 |
| JP7492597B2 (ja) | 2024-05-29 |
| GB202003668D0 (en) | 2020-04-29 |
| CA3175429A1 (en) | 2021-09-16 |
| US12655120B2 (en) | 2026-06-16 |
| AU2021235257A1 (en) | 2022-10-06 |
| CN115515681A (zh) | 2022-12-23 |
| PT4117784T (pt) | 2024-10-07 |
| LT4117784T (lt) | 2024-10-25 |
| EP4117784B1 (en) | 2024-08-28 |
| ES2992600T3 (en) | 2024-12-16 |
| SI4117784T1 (sl) | 2025-03-31 |
| RS66063B1 (sr) | 2024-11-29 |
| US20240254101A1 (en) | 2024-08-01 |
| EP4117784A1 (en) | 2023-01-18 |
| CN115515681B (zh) | 2024-09-03 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HB | Alteration of name in register |
Owner name: NXERA PHARMA UK LIMITED Free format text: FORMER NAME(S): HEPTARES THERAPEUTICS LIMITED |